Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,614 across all filing types
Latest filing 2025-04-28 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
2024年度独立董事述职报告（王焕军）
Board/Management Information Classification · 95% confidence The document is titled '2024 年度独立董事述职报告（王焕军）' which translates to '2024 Annual Independent Director's Work Report (Wang Huanjun)'. It is a detailed report by an independent director about his duties, attendance, and activities during the year 2024. The content includes descriptions of board meetings attended, committee work, communication with auditors, internal control evaluations, and overall governance and supervisory activities. It is a formal report on the independent director's performance and responsibilities over the year, not an announcement or a brief summary. This type of document fits best under Board/Management Information (MANG) as it relates to management and board-level reporting on governance and director duties. It is not an annual report (10-K), audit report (AR), or remuneration report (DEF 14A). The document length and detail confirm it is a full report, not a short announcement or certification. Therefore, the classification is MANG with high confidence.
2025-04-28 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding changes in accounting policies by Shenzhen Haier Bioengineering Co., Ltd. It references new accounting standards issued by the Ministry of Finance of China and explains the impact of these changes on the company's financial statements. The document explicitly states it is an announcement about accounting policy changes and does not contain actual financial statements or detailed financial data. It also mentions that the changes do not require board or shareholder approval. The document length is short (1227 characters), and it serves as a formal disclosure of accounting policy changes rather than a full financial report or audit report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-04-28 Chinese
关于2025年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the company's expected related party transactions for the fiscal year 2025. It includes descriptions of the related parties, transaction types, estimated transaction amounts, pricing principles, and the impact on the company. It also references board and independent director meetings approving the related party transactions. The document is not a financial report, audit report, or earnings release, nor is it a simple announcement of a report publication. It is a regulatory announcement about related party transactions, which is a common type of regulatory filing in Chinese listed companies. Therefore, the document fits best under the category of Regulatory Filings (RNS), as it is a compliance disclosure about related party transactions and does not fit other more specific categories.
2025-04-28 Chinese
内部控制审计报告
Regulatory Filings
2025-04-28 Chinese
关于深圳市海王生物工程股份有限公司2024年度上期内部控制强调事项在本期消除的专项说明
Regulatory Filings
2025-04-28 Chinese
审计委员会对会计师事务所2024年度履职情况评估报告和履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report by the Audit Committee on the performance of the external audit firm for the year 2024. It discusses the audit firm's background, the process of reappointment, and the Audit Committee's supervision and evaluation of the audit firm's work. It does not contain actual financial statements or detailed financial data but rather a supervisory and evaluative report on the audit firm's performance and independence. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of internal or regulatory oversight related to audits, excluding full annual reports. The document length is short (1576 characters), but it is a substantive report, not merely an announcement of a report publication. Therefore, the correct classification is AR with high confidence. FY 2024
2025-04-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.